Related Experiment Video
Updated: May 23, 2026

High-Throughput Expression and Purification of Human Solute Carriers for Structural and Biochemical Studies
Published on: September 29, 2023
Contribution of tumoral and host solute carriers to clinical drug response
Jason A Sprowl1, Torben S Mikkelsen, Hugh Giovinazzo
1Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
Abstract:
Members of the solute carrier family of transporters are responsible for the cellular uptake of a broad range of endogenous compounds and xenobiotics in multiple tissues. Several of these solute carriers are known to be expressed in cancer cells or cancer cell lines, and decreased cellular uptake of drugs potentially contributes to the development of resistance. As result, the expression levels of these proteins in humans have important consequences for an individual's susceptibility to certain drug-induced side effects, interactions, and treatment efficacy. In this review article, we provide an update of this rapidly emerging field, with specific emphasis on the direct contribution of solute carriers to anticancer drug uptake in tumors, the role of these carriers in regulation of anticancer drug disposition, and recent advances in attempts to evaluate these proteins as therapeutic targets.
Insights
Solute carrier transporters influence anticancer drug uptake and resistance. Understanding their role is crucial for improving cancer treatment efficacy and managing side effects.
Area of Science:
- Molecular Biology
- Pharmacology
- Oncology
Background:
- Solute carrier (SLC) transporters facilitate cellular uptake of compounds.
- SLCs are expressed in cancer cells, impacting drug absorption and resistance.
- Altered SLC expression affects drug efficacy, interactions, and side effects.
Purpose of the Study:
- Review the role of SLCs in anticancer drug disposition.
- Highlight SLCs' contribution to drug uptake in tumors.
- Discuss SLCs as potential therapeutic targets in oncology.
Main Methods:
- Literature review of solute carrier transporters in cancer.
- Analysis of SLC expression in cancer cell lines and tumors.
- Evaluation of SLCs in anticancer drug uptake and resistance mechanisms.
Main Results:
- SLCs directly impact anticancer drug uptake in tumor cells.
- SLCs play a significant role in regulating the disposition of anticancer drugs.
- Emerging strategies aim to target SLCs for enhanced cancer therapy.
Conclusions:
- Solute carriers are critical determinants of anticancer drug efficacy.
- Targeting SLCs offers a promising avenue for overcoming drug resistance.
- Further research into SLCs can optimize cancer treatment strategies.
Related Concept Videos
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Hepatic Drug Clearance: Role of Transporters
Membrane Transporters
Transporters are mainly composed of alpha-helices, built from bundles of ten or more helices traversing the plasma membrane. The solute-binding sites are located midway, where some of the helices are broken or distorted, making space for the binding site through...
The Significance of Membrane Transport
Transporters facilitate either an active or passive movement of solutes. They can allow a single-molecule transport down its...
Nonlinear Pharmacokinetics: Role of Transporters
Polymorphisms occurring in drug transporters can alter...

